Literature DB >> 22307672

Cardiomyocyte overexpression of the α1A-adrenergic receptor in the rat phenocopies second but not first window preconditioning.

Xin Zhao1, Jiyeon Park, David Ho, Shumin Gao, Lin Yan, Hui Ge, Siiri Iismaa, Lin Lin, Bin Tian, Dorothy E Vatner, Robert M Graham, Stephen F Vatner.   

Abstract

We examined α(1A)-adrenergic receptor (AR) mediation of preconditioning in a novel α(1A)-AR cardiac transgenic (TG) rat model (α(1A)-TG). Compared with nontransgenic littermates (NTLs), in conscious α(1A)-TG rats, heart rate was reduced, contractility [left ventricle (LV) +dP/dt, ejection fraction, end-systolic elastance] was significantly enhanced, and triple product (LV systolic wall stress × LV +dP/dt × heart rate) was unchanged. However, infarct size (IS)/area at risk (AAR) in response to ischemia-reperfusion (30 min coronary occlusion/3 h reperfusion) was reduced to 35 ± 4.6% in α(1A)-TGs vs. 52 ± 2.2% in NTLs (P < 0.05). Second window preconditioning reduced IS/AAR in NTLs to 29 ± 2.7% but did not afford further protection in α(1A)-TGs. In contrast, with first window preconditioning, IS/AAR was reduced to similar levels in both α(1A)-TGs (12 ± 1.4%) and NTLs (10 ± 1.1%). In untreated α(1A)-TGs, cardioprotection was associated with enhanced myocardial phosphorylated (p)-mitogen/extracellular signal-regulated kinase (MEK), p-extracellular signal-regulated kinase (ERK), and inducible nitric oxide synthase (iNOS) at the protein level, along with a 1.3-fold increase in total nitric oxide synthase activity like in second window preconditioning. Affymetrix microarrays revealed that few genes (4.6% of 3,172 upregulated; 8.8% of 3,498 downregulated) showed directionally similar changes in α(1A)-TGs vs. NTLs subjected to second window preconditioning. Thus, second, but not first, window cardioprotection is evident in α(1A)-TGs in the absence of ischemic preconditioning and is mediated by iNOS activation associated with MEK/ERK phosphorylation. Transcriptionally, however, second window preconditioning is considerably more complex than α(1A)-TG preconditioning, with the alteration of thousands of additional genes affording no further protection than that already available in α(1A)-TG rats.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22307672      PMCID: PMC3330800          DOI: 10.1152/ajpheart.01072.2011

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  33 in total

1.  Localizing extracellular signal-regulated kinase (ERK) in pharmacological preconditioning's trigger pathway.

Authors:  Sebastian Philipp; Stuart D Critz; Lin Cui; Viktoriya Solodushko; Michael V Cohen; James M Downey
Journal:  Basic Res Cardiol       Date:  2005-11-11       Impact factor: 17.165

Review 2.  Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure.

Authors:  Brian C Jensen; Timothy D O'Connell; Paul C Simpson
Journal:  J Mol Cell Cardiol       Date:  2010-11-28       Impact factor: 5.000

3.  alpha1A- but not alpha1B-adrenergic receptors precondition the ischemic heart by a staurosporine-sensitive, chelerythrine-insensitive mechanism.

Authors:  Boyd R Rorabaugh; Sean A Ross; Robert J Gaivin; Robert S Papay; Dan F McCune; Paul C Simpson; Dianne M Perez
Journal:  Cardiovasc Res       Date:  2005-02-01       Impact factor: 10.787

4.  Inhibition of the ER-kinase cascade by PD98059 and UO126 counteracts ischemic preconditioning in pig myocardium.

Authors:  C Strohm; T Barancik; M L Brühl; S A Kilian; W Schaper
Journal:  J Cardiovasc Pharmacol       Date:  2000-08       Impact factor: 3.105

5.  Infarct size-reducing effect of ischemic preconditioning is related to alpha1b-adrenoceptors but not to alpha1a-adrenoceptors in rabbits.

Authors:  T Kariya; S Minatoguchi; T Ohno; K Yamashita; Y Uno; M Arai; M Koshiji; T Fujiwara; H Fujiwara
Journal:  J Cardiovasc Pharmacol       Date:  1997-10       Impact factor: 3.105

6.  Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways.

Authors:  Xi-Ming Yang; J Bradley Proctor; Lin Cui; Thomas Krieg; James M Downey; Michael V Cohen
Journal:  J Am Coll Cardiol       Date:  2004-09-01       Impact factor: 24.094

7.  Alpha-1 adrenergic receptor agonist-induced preconditioning in isolated working rat hearts.

Authors:  A Tosaki; N S Behjet; D T Engelman; R M Engelman; D K Das
Journal:  J Pharmacol Exp Ther       Date:  1995-05       Impact factor: 4.030

8.  Acute and delayed renal protection against renal ischemia and reperfusion injury with A1 adenosine receptors.

Authors:  Jin Deok Joo; Mihwa Kim; Patrick Horst; Jeehee Kim; Vivette D D'Agati; Charles W Emala; H Thomas Lee
Journal:  Am J Physiol Renal Physiol       Date:  2007-10-10

9.  Activation of alpha1B-adrenoceptors alleviates ischemia/reperfusion injury by limitation of mitochondrial Ca2+ overload in cardiomyocytes.

Authors:  Hong Gao; Le Chen; Huang-Tian Yang
Journal:  Cardiovasc Res       Date:  2007-04-21       Impact factor: 10.787

10.  Postconditioning protects human atrial muscle through the activation of the RISK pathway.

Authors:  Vivek Sivaraman; Naveen R Mudalagiri; Carmelo Di Salvo; Shyam Kolvekar; Martin Hayward; John Yap; Bruce Keogh; Derek J Hausenloy; Derek M Yellon
Journal:  Basic Res Cardiol       Date:  2007-06-05       Impact factor: 17.165

View more
  9 in total

Review 1.  Role of Alcohol Oxidative Metabolism in Its Cardiovascular and Autonomic Effects.

Authors:  Mahmoud M El-Mas; Abdel A Abdel-Rahman
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

2.  Oxidative stress and autonomic dysregulation contribute to the acute time-dependent myocardial depressant effect of ethanol in conscious female rats.

Authors:  Badr M Ibrahim; Ming Fan; Abdel A Abdel-Rahman
Journal:  Alcohol Clin Exp Res       Date:  2014-05       Impact factor: 3.455

Review 3.  Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance.

Authors:  Timothy D O'Connell; Brian C Jensen; Anthony J Baker; Paul C Simpson
Journal:  Pharmacol Rev       Date:  2013-12-24       Impact factor: 25.468

4.  Overexpression of Cardiomyocyte α1A-Adrenergic Receptors Attenuates Postinfarct Remodeling by Inducing Angiogenesis Through Heterocellular Signaling.

Authors:  Xin Zhao; Poornima Balaji; Ronald Pachon; Daniella M Beniamen; Dorothy E Vatner; Robert M Graham; Stephen F Vatner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-09-03       Impact factor: 8.311

5.  Metabolomic analysis of two different models of delayed preconditioning.

Authors:  Claudio Bravo; Raymond K Kudej; Chujun Yuan; Seonghun Yoon; Hui Ge; Ji Yeon Park; Bin Tian; William C Stanley; Stephen F Vatner; Dorothy E Vatner; Lin Yan
Journal:  J Mol Cell Cardiol       Date:  2012-11-02       Impact factor: 5.000

6.  Identification and comparative analyses of myocardial miRNAs involved in the fetal response to maternal obesity.

Authors:  Alina Maloyan; Sribalasubashini Muralimanoharan; Steven Huffman; Laura A Cox; Peter W Nathanielsz; Leslie Myatt; Mark J Nijland
Journal:  Physiol Genomics       Date:  2013-08-06       Impact factor: 3.107

Review 7.  Alpha-1-adrenergic receptors in heart failure: the adaptive arm of the cardiac response to chronic catecholamine stimulation.

Authors:  Brian C Jensen; Timothy D OʼConnell; Paul C Simpson
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

8.  Cardiac hypertrophy limits infarct expansion after myocardial infarction in mice.

Authors:  Siiri E Iismaa; Ming Li; Scott Kesteven; Jianxin Wu; Andrea Y Chan; Sara R Holman; John W Calvert; Ahtesham Ul Haq; Amy M Nicks; Nawazish Naqvi; Ahsan Husain; Michael P Feneley; Robert M Graham
Journal:  Sci Rep       Date:  2018-04-17       Impact factor: 4.379

9.  RhoA/ROCK signaling and pleiotropic α1A-adrenergic receptor regulation of cardiac contractility.

Authors:  Ze-Yan Yu; Ju-Chiat Tan; Aisling C McMahon; Siiri E Iismaa; Xiao-Hui Xiao; Scott H Kesteven; Melissa E Reichelt; Marion C Mohl; Nicola J Smith; Diane Fatkin; David Allen; Stewart I Head; Robert M Graham; Michael P Feneley
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.